The Effects of Alteplase 3 to 6 Hours After Stroke in the EPITHET–DEFUSE Combined Dataset | Zendy

Toshiyasu Ogata | Zendy; Sören Christensen | Zendy; Yoshinari Nagakane | Zendy; Henry Ma | Zendy; Bruce Campbell | Zendy; Leonid Churilov | Zendy; Maarten G. Lansberg | Zendy; Matús Straka | Zendy; Deidre Anne De Silva | Zendy; Michael Mlynash | Zendy; Roland Bammer | Zendy; JeanMarc Olivot | Zendy; Patricia Desmond | Zendy; Gregory W. Albers | Zendy; Stephen M. Davis | Zendy; Geoffrey A. Donnan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Effects of Alteplase 3 to 6 Hours After Stroke in the EPITHET–DEFUSE Combined Dataset

Author(s) -

Toshiyasu Ogata,

Sören Christensen,

Yoshinari Nagakane,

Henry Ma,

Bruce Campbell,

Leonid Churilov,

Maarten G. Lansberg,

Matús Straka,

Deidre Anne De Silva,

Michael Mlynash,

Roland Bammer,

JeanMarc Olivot,

Patricia Desmond,

Gregory W. Albers,

Stephen M. Davis,

Geoffrey A. Donnan

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.112.668301

Subject(s) - medicine , placebo , stroke (engine) , thrombolysis , perfusion scanning , fibrinolytic agent , clinical endpoint , randomized controlled trial , perfusion , clinical trial , intracerebral hemorrhage , cardiology , anesthesia , surgery , radiology , tissue plasminogen activator , myocardial infarction , pathology , mechanical engineering , alternative medicine , subarachnoid hemorrhage , engineering

Two phase 2 studies of alteplase in acute ischemic stroke 3 to 6 hours after onset, Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET; a randomized, controlled, double-blinded trial), and Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution Study (DEFUSE; open-label, treatment only) using MR imaging-based outcomes have been conducted. We have pooled individual patient data from these to assess the response to alteplase. The primary hypothesis was that alteplase would significantly attenuate infarct growth compared with placebo in mismatch-selected patients using coregistration techniques.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research